Beyond bone health, the effects of GLP-1Ra on musculoskeletal health remain to be elucidated [82]
Unless one of the new pipeline drugs shows another differentiator like alzheimer protection, or becomes combined with something like a myostatin inhibitor that can protect muscle-mass loss, then I believe were going to see the semaglutide patent release cause a nosedive for every other branded GLP-1 on the market in 2032
Mutritional management in the elderly
"In my practice, we go down in dose gradually, the same as we go up, in order to monitor changes and maintain control," she says
Committee recommendations, while non-binding, heavily influence FDA decisions
Swelling is another common reaction